



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

**FILE COPY**

November 13, 2006

Robert W. Pollock  
Lachman Consultant Services, Inc.  
1600 Stewart Avenue  
Westbury, NY 11590

Dear Mr. Pollock:

Your petition requesting the Food and Drug Administration to determine whether Prevacid NapraPAC, 15 mg/250 mg (lansoprazole delayed-release, 15 mg capsules and naproxen 250 mg tablets kit) (NDA No. 021507) by Tap Pharm, has been voluntarily withdrawn or withheld from sale for safety or efficacy reasons, was received by this office on 11/13/2006. It was assigned docket number 2006P-0462/CP1 and it was filed on 11/13/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe  
Division of Dockets Management  
Office of Management Programs  
Office of Management

2006P-0462

ACK1